All News

2018

September

Media Release / Sep 21, 2018

Sandoz receives positive CHMP opinion for proposed biosimilar pegfilgrastim

Read More
Media Release / Sep 06, 2018

Novartis to divest the Sandoz US dermatology business and generic US oral solids portfolio to Aurobindo

Read More

August

Melanoma survivor talks skin cancer prevention and detection
Story / Aug 29, 2018

The ABCDEs of melanoma prevention and detection

Melanoma survivor T.J. Sharpe discusses skin cancer prevention and detection, and shares tips on how to keep you and your loved ones safe in the sun.

Read More
Media Release / Aug 29, 2018

European Commission approves Novartis combination therapy Tafinlar® + Mekinist® for adjuvant treatment of BRAF V600 mutation-positive melanoma

Read More
Media Release / Aug 27, 2018

Novartis receives European Commission approval of its CAR-T cell therapy, Kymriah® (tisagenlecleucel)

Read More
Media Release / Aug 23, 2018

SOLAR-1 trial of Novartis investigational alpha-specific PI3K inhibitor BYL719 (alpelisib) meets primary endpoint in HR+/HER2- advanced breast cancer with PIK3CA mutation

Read More

July

Media Release / Jul 27, 2018

Sandoz receives European Commission approval for biosimilar Hyrimoz® (adalimumab)

Read More
Media Release / Jul 27, 2018

Novartis combination Tafinlar® + Mekinist® receives positive CHMP opinion for adjuvant treatment of BRAF V600 mutation-positive melanoma

Read More
Media Release / Jul 18, 2018

Novartis Kisqali® now first and only CDK4/6 inhibitor indicated in US as first-line therapy specifically for premenopausal women; and as initial therapy with fulvestrant in postmenopausal women

Read More
Media Release / Jul 18, 2018

Novartis delivers solid growth in second quarter and continues transformation to a focused medicines company

Read More

Pages

Related Links

Annual Report 2017

Review the strategy and annual performance of Novartis and read letters from our Chairman and CEO.

Learn More